Citigroup Upgrades Haemonetics to Buy from Neutral
Fintel reports that on September 17, 2026, Citigroup upgraded their outlook for Haemonetics (NYSE:HAE) from Neutral to Buy. Citigroup had maintained a Neutral rating on August 7, 2026.
Recent maintained ratings include Raymond James (Outperform, September 3, 2026), Baird (Outperform, August 21, 2026), Barrington Research (Outperform, August 19, 2026) and BTIG (Buy, August 18, 2026).
As of the current recommendation period of September 1, 2026, the aggregate recommendation total for Haemonetics is 15, consisting of 5 strong buy, 6 buy, 4 hold, 0 sell, and 0 strong sell recommendations. This represents 73.3% positive recommendations and 26.7% hold recommendations.
The consensus price target data as of September 15, 2026, shows a current consensus target mean of $113.11 and a median of $117.30. The mean target represents a current consensus target implied change of +6.46% from the pre-action closing price. The prior consensus target mean was $110.84 as of August 28, 2026, representing a consensus target revision of +2.04%.
On September 16, 2026, the day before the rating action, the stock closed at $106.24. This pre-action close represents a price change of +2.99% over one week from a baseline close of $103.16 on September 9, 2026, and a price change of +17.00% over one month from a baseline close of $90.80 on August 14, 2026.
In its latest earnings report on August 6, 2026, Haemonetics reported actual earnings per share of 1.14, compared to the estimate of 1.0876, representing a surprise of +4.82%. Actual revenue was $339,380,000.00, compared to the estimate of $331,172,667.00. According to the company's EX-99.1 filing dated August 6, 2026, titled "Haemonetics Reports First Quarter Fiscal 2027 Results; Raises Total Company Fiscal 2027 Guidance," the company reported first-quarter revenue of $339 million, representing a 5.6% increase, with organic revenue increasing 5.9%. The filing also reported earnings per diluted share of $0.72, adjusted earnings per diluted share of $1.14, and cash flow from operating activities of $52 mill. A subsequent Form 8-K filed on August 18, 2026, lists the company's principal executive offices at 125 Summer Street, Boston, MA 02110.
Haemonetics Corporation, based in Boston, Massachusetts, USA, operates primarily in the healthcare sector, focusing on blood and plasma supplies and services and the manufacturing and development of products for blood collection, separation, and processing.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 17, 2026 | Citigroup | Neutral | Buy | upgrade |
| September 3, 2026 | Raymond James | Outperform | Outperform | maintained |
| August 21, 2026 | Baird | Outperform | Outperform | maintained |
| August 19, 2026 | Barrington Research | Outperform | Outperform | maintained |
| August 18, 2026 | BTIG | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.